NEW YORK (GenomeWeb News) - ExonHit Therapeutics said today that it has amended its longstanding partnership with bioMerieux in order to gain commercial rights to cancer diagnostic kits developed through the agreement.
 
The amended agreement also gives bioMerieux “greater flexibility to initiate new research and development projects in that field,” ExonHit said.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

23andMe's Anne Wojcicki ponders DNA and what it means to be human in a New York Times essay.

A new estimate places the last universal common ancestor to life on Earth as living 3.9 billion years ago, Inverse reports.

In PNAS this week: retinitis pigmentosa gene therapy, role of microbiome in growth stunting, and more.

Bloomberg reports that researchers and drug companies are modeling anti-obesity treatments after the rare genetic condition essential fructosuria.